Evaluate Safety and Effectiveness of MBX-102 in Type 2 Diabetes Patients With Poor Glycemic Control on Metformin

This study has been terminated.
(MBX-102 did not meet the target efficacy profile of HbA1c change.)
Sponsor:
Information provided by (Responsible Party):
CymaBay Therapeutics, Inc.
ClinicalTrials.gov Identifier:
NCT00814372
First received: December 22, 2008
Last updated: March 30, 2015
Last verified: March 2015
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study has been terminated.
  Study Completion Date: February 2010
  Primary Completion Date: February 2010 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: February 16, 2015